nach oben

Medical Oncology

Erschienen in:

01.06.2013 | Original Paper

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

verfasst von: Sensen Zhang, Jiaren Xu, Shuang Wu, Rong Wang, Xiaoyan Qu, Wenjun Yu, Jiangyong Li, Lijuan Chen

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory family, which plays an important role in many lymphoid and myeloid malignancies. In the current study, using immunohistochemical staining, we found that IRF4 only expressed in plasma cells in bone marrow biopsy samples of multiple myeloma. IRF4-positive patients displayed increased disease stage (Durie–Salmon stage, p = 0.026; and International Staging System, p = 0.005). Silencing IRF4 in myeloma cell lines could inhibit myeloma cells proliferation and induce myeloma cell apoptosis, partly by JNK/Jun pathway. These results demonstrate that IRF4 plays important roles in myelomagenesis and disease progression.

Yuregir OO, Sahin FI, Yilmaz Z, Kizilkilic E, Karakus S, Ozdogu H. Fluorescent in situ hybridization studies in multiple myeloma. Hematology. 2009;14:90–4.PubMedCrossRef

Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, Juttner A, Schnurr T, Cremer F, et al. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet. 2006;167:20–5.PubMedCrossRef

Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A, et al. Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia. 1999;13:1812–6.PubMedCrossRef

Iida S, Rao PH, Butler M, Corradini P, Boccadoro M, Klein B, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17:226–30.PubMedCrossRef

Gualco G, Weiss LM, Bacchi CE. MUM1/IRF4: a review. Appl Immunohistochem Mol Morphol. 2010;18:301–10.PubMedCrossRef

Yamamoto M, Kato T, Hotta C, Nishiyama A, Kurotaki D, Yoshinari M, et al. Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development. PLoS One. 2011;6:e25812.PubMedCrossRef

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.PubMedCrossRef

Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS, et al. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One. 2011;6:e22628.PubMedCrossRef

Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, et al. IRF4 mutations in chronic lymphocytic leukemia. Blood. 2011;118:2827–9.PubMedCrossRef

10.

Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, et al. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. 2008;22:441–5.PubMedCrossRef

11.

Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226–31.PubMedCrossRef

12.

Balakumaran A, Robey PG, Fedarko N, Landgren O. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn. 2010;10:465–80.PubMedCrossRef

13.

Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res. 2011;110:19–42.PubMedCrossRef

14.

Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64:2016–23.PubMedCrossRef

15.

Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007;109:4470–7.PubMedCrossRef

16.

Xu WD, Pan HF, Ye DQ, Xu Y. Targeting IRF4 in autoimmune diseases. Autoimmun Rev. 2012;11:918–24.PubMedCrossRef

17.

Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012;44:237–44.PubMedCrossRef

18.

Glasmacher E, Agrawal S, Chang AB, Murphy TL, Zeng W, Vander Lugt B, et al. A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science. 2012;338:975–80.PubMedCrossRef

19.

Podar K, Raab MS, Tonon G, Sattler M, Barila D, Zhang J, et al. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007;67:1680–8.PubMedCrossRef

20.

Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010;115:61–70.PubMedCrossRef

Titel: IRF4 promotes cell proliferation by JNK pathway in multiple myeloma
verfasst von: Sensen Zhang
Jiaren Xu
Shuang Wu
Rong Wang
Xiaoyan Qu
Wenjun Yu
Jiangyong Li
Lijuan Chen
Publikationsdatum: 01.06.2013
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-013-0594-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

IRF4 promotes cell proliferation by JNK pathway in multiple myeloma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Clinical implications of CIP2A protein expression in breast cancer

Treatment for hepatitis C virus–induced portal hypertension in leukemic children

CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from Central South China

IL-32 expression is an independent prognostic marker for gastric cancer

The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie